4/6
08:47 pm
bcax
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration [Yahoo! Finance]
Low
Report
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration [Yahoo! Finance]
4/3
09:28 am
bcax
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
4/3
08:30 am
bcax
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
3/31
03:37 pm
bcax
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]
Low
Report
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]
3/31
12:49 pm
bcax
Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.
Low
Report
Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.
3/31
10:20 am
bcax
Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
Low
Report
Bicara Therapeutics (BCAX) had its price target raised by Wells Fargo & Company from $11.00 to $16.00. They now have an "equal weight" rating on the stock.
3/31
10:20 am
bcax
Bicara Therapeutics (BCAX) had its "outperform" rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.
Low
Report
Bicara Therapeutics (BCAX) had its "outperform" rating reaffirmed by Wedbush. They now have a $30.00 price target on the stock.
3/31
09:02 am
bcax
Bicara Therapeutics (BCAX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.
Medium
Report
Bicara Therapeutics (BCAX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $31.00 price target on the stock.
3/31
08:02 am
bcax
Bicara Therapeutics (BCAX) had its price target raised by HC Wainwright from $40.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
Bicara Therapeutics (BCAX) had its price target raised by HC Wainwright from $40.00 to $42.00. They now have a "buy" rating on the stock.
3/30
07:19 pm
bcax
Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
Low
Report
Bicara Therapeutics Inc (BCAX) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
3/30
12:55 pm
bcax
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? [Yahoo! Finance]
Low
Report
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? [Yahoo! Finance]
3/30
10:29 am
bcax
Bicara Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Bicara Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/30
08:05 am
bcax
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/30
07:30 am
bcax
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Medium
Report
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
3/26
05:56 pm
bcax
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. [Yahoo! Finance]
Low
Report
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder. [Yahoo! Finance]
3/25
08:42 am
bcax
Bicara Therapeutics (BCAX) is now covered by Bank of America Corporation. They set a "buy" rating and a $35.00 price target on the stock.
Low
Report
Bicara Therapeutics (BCAX) is now covered by Bank of America Corporation. They set a "buy" rating and a $35.00 price target on the stock.
3/23
08:46 am
bcax
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET [Yahoo! Finance]
Low
Report
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET [Yahoo! Finance]
3/23
08:30 am
bcax
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
Low
Report
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
3/13
12:28 am
bcax
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference [Yahoo! Finance]
Low
Report
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference [Yahoo! Finance]
3/7
07:03 pm
bcax
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan [Yahoo! Finance]
Medium
Report
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan [Yahoo! Finance]
3/4
09:09 am
bcax
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/4
08:30 am
bcax
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2/26
04:01 pm
bcax
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/24
11:13 pm
bcax
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
2/24
04:01 pm
bcax
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Bicara Therapeutics Announces Proposed Public Offering of Common Stock